Literature DB >> 8913413

Corticosteroids in tuberculosis.

J R Cisneros1, K M Murray.   

Abstract

OBJECTIVE: To examine the effects of corticosteroids used for concomitant disease states in patients with latent or active tuberculosis (TB). The role of corticosteroids in the treatment of extrapulmonary TB is also discussed. DATA SOURCES: A MEDLINE search was conducted for the years 1953-1995. The International Pharmaceutical Abstracts service was also used to conduct an extensive literature review. In addition, relevant articles were cross-referenced to screen for additional information. STUDY SELECTION/DATA EXTRACTION: During the literature review, emphasis was placed on human studies and individual case reports. DATA SYNTHESIS: The resurgence of TB in this decade has affected many populations, especially immunocompromised patients. These patients may need corticosteroid therapy for various concomitant diseases that might predispose a patient to develop primary TB infection or reactivate latent TB infection. In appropriate patients, prophylaxis with isoniazid is recommended. Corticosteroid therapy may benefit patients with some forms of extrapulmonary TB. After steroid therapy, improved survival and more rapid reduction of tuberculous symptoms have been noted in cases of tuberculous pleurisy, endobronchial TB, tuberculous meningitis, and tuberculous pericarditis. Corticosteroids may also be useful in controlling both fever and hypersensitivity reactions in pulmonary and extrapulmonary TB, although not routinely used for this purpose.
CONCLUSIONS: Corticosteroids may play an important role in TB infection by promoting reactivation of latent infection. Corticosteroids may modify symptoms of some forms of extrapulmonary TB, although randomized, placebo-controlled studies are needed before corticosteroids will have a definitive place in the standard therapy of TB.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913413     DOI: 10.1177/106002809603001115

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  18 in total

Review 1.  Role of cytokines in the innate immune response to intracellular pathogens.

Authors:  S Stenger; M Röllinghoff
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Reactivation of latent tuberculosis: variations on the Cornell murine model.

Authors:  C A Scanga; V P Mohan; H Joseph; K Yu; J Chan; J L Flynn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  IL-10-producing T cells suppress immune responses in anergic tuberculosis patients.

Authors:  V A Boussiotis; E Y Tsai; E J Yunis; S Thim; J C Delgado; C C Dascher; A Berezovskaya; D Rousset; J M Reynes; A E Goldfeld
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 4.  The current state of tuberculosis vaccines.

Authors:  David A Hokey; Ann Ginsberg
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

Review 5.  Laboratory evaluation of the IFN-γ circuit for the molecular diagnosis of Mendelian susceptibility to mycobacterial disease.

Authors:  Ana Esteve-Solé; Ithaisa Sologuren; María Teresa Martínez-Saavedra; Àngela Deyà-Martínez; Carmen Oleaga-Quintas; Rubén Martinez-Barricarte; Andrea Martin-Nalda; Manel Juan; Jean-Laurent Casanova; Carlos Rodriguez-Gallego; Laia Alsina; Jacinta Bustamante
Journal:  Crit Rev Clin Lab Sci       Date:  2018-03-04       Impact factor: 6.250

6.  Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis.

Authors:  Liana Tsenova; Bande Mangaliso; George Muller; Yong Chen; Victoria H Freedman; David Stirling; Gilla Kaplan
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children.

Authors:  Benjamin L Laskin; Jens Goebel; Jeffrey R Starke; Daniel P Schauer; Mark H Eckman
Journal:  Am J Kidney Dis       Date:  2012-07-10       Impact factor: 8.860

8.  Corticosteroids for bacterial corneal ulcers.

Authors:  M Srinivasan; P Lalitha; R Mahalakshmi; N V Prajna; J Mascarenhas; J D Chidambaram; S Lee; K C Hong; M Zegans; D V Glidden; S McLeod; J P Whitcher; T M Lietman; N R Acharya
Journal:  Br J Ophthalmol       Date:  2008-10-01       Impact factor: 4.638

9.  Endobronchial tuberculosis presenting as right middle lobe syndrome: clinical characteristics and bronchoscopic findings in 22 cases.

Authors:  Ho Cheol Kim; Hyeon Sik Kim; Seung Jun Lee; Yi Yeong Jeong; Kyoung-Nyeo Jeon; Jong Deok Lee; Young Sil Hwang
Journal:  Yonsei Med J       Date:  2008-08-30       Impact factor: 2.759

10.  Myasthenia gravis aggravated by steroid-induced isolated mediastinal tuberculous lymphadenitis.

Authors:  Tai-Seung Nam; Man-Seok Park; Kang-Ho Choi; Hyun-Jung Jung; Geum-Jin Yoon; Seong-Min Choi; Byeong-Chae Kim; Myeong-Kyu Kim; Ki-Hyun Cho
Journal:  J Clin Neurol       Date:  2010-12-31       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.